secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alkermes plc. (ALKS)
CIK:        0001520262
Form:       8-K
Filed at:   2023-10-25T23:59:59+00:00
Accession:  0000950170-23-054999
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alkermes Q3 2023 revenue $380.9M, GAAP net income $47.8M; reiterates FY guidance; oncology split in Nov
--------------------------------------------------------------------------------

- Total Q3 revenues $380.9M vs $252.4M YoY; proprietary product sales up 16% to $231.8M.
- GAAP net income $47.8M ($0.28 diluted EPS) vs GAAP net loss of $64.0M YoY; non-GAAP net income $109.5M ($0.64 diluted EPS).
- LYBALVI net sales $50.7M (+87% YoY); VIVITROL $99.3M (+3%); ARISTADA $81.8M (+8%).
- Cash & investments $995.6M; debt $291.4M; reiterates FY2023 guidance.
- Expects oncology spin-off (Mural) Nov 2023 with $275M; settled VIVITROL patent suit with Teva (generic Jan 2027).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1520262/000095017023054999/0000950170-23-054999-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1520262/000095017023054999/alks-20231025.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-054999

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer